Profile for Assessment regarding venous thromboembolism likelihood within freshly identified several myeloma individuals receiving bortezomib, lenalidomide, dexamethasone (RVD) or perhaps carfilzomib, lenalidomide, dexamethasone (KRD) together with pain killers as we (kenyasilk16)